Your patients’ stories are unique. Lucence provides insights to help guide personalized treatment so that your patients can receive the best care possible.
Our wide portfolio of tests aims to ensure that there’s a test for every need.
Our solutions for treatment selection:
LiquidHALLMARK is an ultrasensitive blood test designed to detect tumor-derived ctDNA and ctRNA to identify cancer-related mutations and biomarkers with a single blood draw.
LiquidMARK is a focused sub-panel for targeted cancer types. It uses the same test process as LiquidHALLMARK to detect
tumor-derived ctDNA in the blood to identify cancer-related mutations and biomarkers with a single blood draw.
Our solutions for treatment response monitoring:
LucenceMONITOR is a minimal residual disease (MRD) test that screens for the recurrence of 6 cancers: breast, colorectal, lung, liver, pancreatic, and biliary tract cancer.
The test uses detects circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) from cancer cells to track tumor-specific mutations.
Ordering Process (Liquid)
Ordering Process (Tissue)
Frequently Asked Questions
Our laboratory-developed tests (LDT) are validated and performed in our CLIA-certified, CAP-accredited lab.
Unlike an FDA-approved test, an LDT allows us to update the assay rapidly as new biomarkers emerge or new clinical evidence comes in, which is critical in a fast-moving field like oncology.
Among other scenarios, FDA approval is typically pursued when the test is being used as a companion diagnostic, where it must match a specific drug indication, but that also locks the design and limits flexibility.Contact us to request for a sample collection kit.
After ordering the test, patients will be required to either draw blood or undergo tissue biopsy. The blood or tissue sample is then sent to Lucence laboratory for testing. The report is generated and sent over to your clinic. Turnaround time will vary across different tests.
Refer to the list of our solutions here.LiquidHALLMARK® combines ctDNA and ctRNA analysis, enabling high sensitivity for detecting fusions and other alterations often missed by ctDNA-only panels.
In our LIQUIK study, LiquidHALLMARK ctDNA + ctRNA detected 15.6% (52/68 vs 45/68) additional tissue-confirmed, NCCN guideline-recommended biomarkers for NSCLC than the ctDNA only FDA-approved test. It also demonstrated superiority by detecting 8.8% more biomarker-positive patients compared to the FDA-approved ctDNA only test.
Read the full publication
Our strategic collaborator
Our research collaborators
